This is just catching upWhen the company announced they regained control over their IP (data), the only people that cared were existing shareholders. Further, another announced penny PP did little to stir outlier investor interest. Times have changed quickly. One particular whale picked up a ton of paper and brought some new people in with him. Given the space this company is in, the stock could even run on peripheral sector news. Stem cell tech is hot in general and autologous stem cell tech is hot specifically especially with the right clinical data. Peer valuations tell the tale of HEM's escalating share price. This stock despite the current move to the upside remains grossly undervalued.